{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"PFS will be calculated for all patients from the date of transplant until the time of progression, relapse, death, or the date the patient was last known to be in remission. Progressive disease is defined as greater than 25% increase in serum or urine M proteins compared to best response status after autologous transplant and/or appearance of new lytic bone lesions or plasmocytomas.","groups":[{"description":"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -3 and intermediate-dose melphalan IV over 15-20 minutes on day -2. Patients also undergo low-dose TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.\n\nIMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 180 (related donors) or on days -3 to 100 with taper to day 180 (unrelated donors). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related donors) or TID on days 0-40 with taper to day 96 (unrelated donors).\n\nfludarabine phosphate: Given IV melphalan: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given PO\n\nnonmyeloablative allogeneic hematopoietic stem cell transplantation: Undergo reduced-intensity allogeneic PBSCT\n\nperipheral blood stem cell transplantation: Undergo reduced-intensity allogeneic PBSCT\n\nlaboratory biomarker analysis: Correlative s","id":"OG000","title":"Related Donor"},{"description":"PREPARATIVE REGIMEN: Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -3 and intermediate-dose melphalan IV over 15-20 minutes on day -2. Patients also undergo low-dose TBI on day 0.\n\nTRANSPLANTATION: Patients undergo allogeneic PBSCT on day 0.\n\nIMMUNOSUPPRESSION: Patients receive cyclosporine PO BID on days -3 to 80 with taper to day 180 (related donors) or on days -3 to 100 with taper to day 180 (unrelated donors). Patients also receive mycophenolate mofetil PO BID on days 0-27 (related donors) or TID on days 0-40 with taper to day 96 (unrelated donors).\n\nfludarabine phosphate: Given IV melphalan: Given IV\n\ntotal-body irradiation: Undergo TBI\n\nmycophenolate mofetil: Given PO\n\ncyclosporine: Given PO\n\nnonmyeloablative allogeneic hematopoietic stem cell transplantation: Undergo reduced-intensity allogeneic PBSCT\n\nperipheral blood stem cell transplantation: Undergo reduced-intensity allogeneic PBSCT\n\nlaboratory biomarker analysis: Correlative s","id":"OG001","title":"Unrelated Donor"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"There were 4 patients who, although they did not have progression/relapse, died before the 1 year mark, and thus are not included in the 1 year PFS count.","reportingStatus":"POSTED","timeFrame":"At 1 year post-transplant","title":"PFS","type":"PRIMARY","unitOfMeasure":"Participants"}